PT-141 for Health & Longevity - Quick Reference Sheet

PT-141 for Health & Longevity

Created on 07/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A lab-made peptide, given by injection on demand, that acts on the brain to raise sexual desire and arousal rather than blood flow. Approved for premenopausal women with distressing low desire and used off-label in men. Benefits are real but small and overlap heavily with placebo; nausea, flushing, and headache are common. (Full Review)

Protocol

Dose
1.75 mg
Subcutaneous injection into abdomen or thigh
Timing
45 min before
On demand, before anticipated sexual activity
Frequency
≤1 per 24 h
No more than 8 doses per month
Time to effect
Onset
~45 min
Acute, on-demand effect the same day
Overall benefit
Several uses
Judged over several separate uses, not cumulative
Half-life
~2.7 h
Short; supports episodic, on-demand use

Benefits

Contraindications
  • Uncontrolled hypertension (≥140/90 mmHg)
  • Known cardiovascular disease
  • Cardiovascular event (heart attack or stroke) within prior 6 months
  • Pregnancy
Key Interactions
  • Oral naltrexone
  • Indomethacin
  • OTC NSAIDs (ibuprofen, naproxen)
  • Blood-pressure-raising agents (stimulant pre-workouts, high-dose caffeine, yohimbine, licorice root)
  • PDE5 inhibitors (sildenafil, tadalafil)

Risk & Side Effects

  • High: Nausea; flushing; headache
  • Medium: Focal hyperpigmentation; transient blood pressure increase and heart rate decrease; injection site reactions
  • Low: Lowered naltrexone levels
  • Speculative: Theoretical melanocyte and melanoma concern

Monitoring

Marker Target Why
Blood pressure ~110–125 / 70–80 mmHg Transiently raised; confirm control before and during use
Resting heart rate 50–70 bpm Transient decrease reported; baseline aids interpretation
Skin and moles No new or changing pigmented lesions Melanocyte stimulation can darken skin and moles
eGFR >90 mL/min/1.73m² Partly cleared by the kidneys

Cadence: Blood pressure before initiation and after the first one or two doses, then periodically; skin and mole review at baseline and at least annually, with more frequent checks in frequent users.

Qualitative Assessment

  • Improvement in sexual desire and interest
  • Reduction in personal distress related to low desire
  • Adequacy of sexual arousal and satisfaction with sexual events
  • Tolerability of nausea and other side effects
  • Overall relationship and quality-of-life satisfaction